CF PharmTech, Inc. announced that its co-founders and executive directors—Dr. Liang Bill Wenqing (Chairperson and CEO) and Dr. Li Li Bovet (Chief Scientific Officer)—have each signed voluntary undertakings to extend the lock-up of their shareholdings by an additional six months beyond the statutory 12-month period that ends on 7 October 2026. The new lock-up will now run from 8 October 2026 through 7 April 2027, inclusive.

The extended lock-up covers the following “Relevant Shares” in which the two executives have a direct or indirect beneficial interest: • Dr. Liang Bill Wenqing: 15.68 million H shares and 10.45 million unlisted shares held via Suzhou Pyramid Investment Management Enterprise (Limited Partnership). • Dr. Li Li Bovet: 14.38 million H shares and 9.59 million unlisted shares held via Suzhou Meizhongrui Investment Management Enterprise (Limited Partnership). • Joint employee-incentive interests: a combined 7.56 million shares held through the same two investment vehicles.

Shares associated with the company’s 2024 share incentive scheme, held by other partnership entities, are explicitly excluded from the new lock-up.

During the extended period, the executives undertake not to sell, transfer, or otherwise dispose of any of the Relevant Shares except as permitted under applicable laws, Hong Kong Listing Rules, and the company’s internal policies.

Management states that the voluntary extension reflects confidence in the group’s long-term strategy and aligns leadership interests with those of all shareholders. Investors are advised to exercise caution when trading the company’s securities.